ZA202406196B - Crf2 receptor agonists and their use in therapy - Google Patents

Crf2 receptor agonists and their use in therapy

Info

Publication number
ZA202406196B
ZA202406196B ZA2024/06196A ZA202406196A ZA202406196B ZA 202406196 B ZA202406196 B ZA 202406196B ZA 2024/06196 A ZA2024/06196 A ZA 2024/06196A ZA 202406196 A ZA202406196 A ZA 202406196A ZA 202406196 B ZA202406196 B ZA 202406196B
Authority
ZA
South Africa
Prior art keywords
therapy
sarcopenia
receptor agonists
obesity
crf2
Prior art date
Application number
ZA2024/06196A
Other languages
English (en)
Inventor
Philip Janiak
Marie-Laure Ozoux
Daniela Roversi
Elisabetta Bianchi
Martina Tripepi
Alessia Santoprete
Original Assignee
Corteria Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corteria Pharmaceuticals filed Critical Corteria Pharmaceuticals
Publication of ZA202406196B publication Critical patent/ZA202406196B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
ZA2024/06196A 2022-02-23 2024-08-13 Crf2 receptor agonists and their use in therapy ZA202406196B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22158188.7A EP4234574A1 (en) 2022-02-23 2022-02-23 Crf2 receptor agonists and their use in therapy
PCT/EP2023/054317 WO2023161229A1 (en) 2022-02-23 2023-02-21 Crf2 receptor agonists and their use in therapy

Publications (1)

Publication Number Publication Date
ZA202406196B true ZA202406196B (en) 2025-03-26

Family

ID=80819682

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2024/06196A ZA202406196B (en) 2022-02-23 2024-08-13 Crf2 receptor agonists and their use in therapy

Country Status (15)

Country Link
US (1) US20260001928A1 (cg-RX-API-DMAC10.html)
EP (3) EP4234574A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025508820A (cg-RX-API-DMAC10.html)
KR (1) KR20240153565A (cg-RX-API-DMAC10.html)
CN (1) CN118843638A (cg-RX-API-DMAC10.html)
AU (1) AU2023224327A1 (cg-RX-API-DMAC10.html)
CA (1) CA3247142A1 (cg-RX-API-DMAC10.html)
ES (1) ES3063881T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20260115T1 (cg-RX-API-DMAC10.html)
IL (1) IL314055A (cg-RX-API-DMAC10.html)
IS (1) IS050770A (cg-RX-API-DMAC10.html)
MX (1) MX2024010296A (cg-RX-API-DMAC10.html)
PL (1) PL4482578T3 (cg-RX-API-DMAC10.html)
WO (1) WO2023161229A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202406196B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260089954A (ko) * 2023-11-17 2026-06-16 구브라 에이/에스 hCRHR2 선택적 폴리펩타이드
WO2026064495A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2026064486A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2114437A2 (en) * 2006-10-16 2009-11-11 ConjuChem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2019140030A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
US12679878B2 (en) * 2020-08-19 2026-07-14 Sanofi CRF2 receptor agonists and their use in therapy

Also Published As

Publication number Publication date
EP4482578C0 (en) 2025-12-24
CA3247142A1 (en) 2023-08-31
EP4482578A1 (en) 2025-01-01
CN118843638A (zh) 2024-10-25
IL314055A (en) 2024-09-01
WO2023161229A1 (en) 2023-08-31
AU2023224327A1 (en) 2024-08-29
EP4482578B1 (en) 2025-12-24
EP4781998A2 (en) 2026-07-29
MX2024010296A (es) 2024-09-18
JP2025508820A (ja) 2025-04-10
IS050770A (is) 2024-10-15
KR20240153565A (ko) 2024-10-23
HRP20260115T1 (hr) 2026-03-13
ES3063881T3 (en) 2026-04-21
EP4234574A1 (en) 2023-08-30
PL4482578T3 (pl) 2026-03-16
US20260001928A1 (en) 2026-01-01

Similar Documents

Publication Publication Date Title
ZA202301784B (en) Crf2 receptor agonists and their use in therapy
JP7541600B2 (ja) Gipアゴニスト化合物及び方法
US20240173309A1 (en) Lipidated peptide inhibitors of interleukin-23 receptor
JP5755653B2 (ja) ペプチド性glp−2アゴニスト
MX2022010011A (es) Inhibidores de prmt5 novedosos.
CZ325496A3 (en) Amino acid derivatives, process for preparing and pharmaceutical compositions containing thereof
JP2020128424A (ja) 消化器疾患の治療
JP2005532330A5 (cg-RX-API-DMAC10.html)
CN105899529A (zh) 胰高血糖素类似物
MX2024010296A (es) Agonistas del receptor de crf2 y su uso en terapia.
NO20075354L (no) Forbindelser, isomerer og farmasoytiske akseptable salter derav, som vanilloidreseptorantagoniser, og farmasoytiske preparater inneholdende slike
JP2004521123A5 (cg-RX-API-DMAC10.html)
JP2016519106A5 (cg-RX-API-DMAC10.html)
TW201804994A (zh) 抗真菌劑
US11578112B2 (en) Long-acting adrenomedullin derivative conjugated with Fc region of immunoglobulin
JP5319920B2 (ja) ナトリウムおよび/またはカルシウムチャンネル選択的調節因子として活性のある医薬の製造のための(ハロベンジルオキシ)ベンジルアミノ−プロパンアミドの使用
WO2020236690A9 (en) Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
US9657062B2 (en) Ghrelin analogues
US8921306B2 (en) Nociceptin mimetics
JP2008512405A5 (cg-RX-API-DMAC10.html)
US9617305B2 (en) Treatments for gastrointestinal disorders
AU2020334194A1 (en) Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions
EP2460826A1 (en) Motilin-like peptide compound having transmucosal absorbability imparted thereto
CN100339079C (zh) 取代的咪唑烷类化合物,其制备方法,其作为药物或诊断剂的用途以及含有取代的咪唑烷类化合物的药物
IL276474B2 (en) Modified bisphenyl butanoic ester derivatives as nep inhibitors